Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimise product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalised medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programmes and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians.
Through our broad capabilities and vast experience, Catalent thrives on tailoring customised solutions to accelerate, simplify, and de-risk clinical development and commercial supply of our partners’ programs. With global technologies that span from pre-clinical and first-in-human studies to commercial strategy and life-cycle management, Catalent has the breadth of solutions to meet customer needs. Combined with our extensive scientific expertise and robust network of industry contacts, Catalent can help develop and manufacture the right product to align with any strategy, whether trying to achieve the next funding milestone or long-term commercial success. Focused on delivering treatments to help people live better, healthier lives, Catalent is the ideal CDMO partner in the industry.
Oral Drug Development and Manufacturing
Catalent is a global leader in in developing and manufacturing oral solid dosage forms. Offering integrated early phase drug development solutions including PBPK modelling, molecule characterisation, bioavailability enhancement, API-sparing development techniques and phase-appropriate dose forms, Catalent can help accelerate molecules from candidate to clinic and market. With a proven track record in the successful scale-up of manufacturing processes and seamless technology transfers, Catalent leverages expertise and scale across a global network to match the best technologies to optimal oral dose forms to enable successful programmes. From early phase development through clinical supply and commercial manufacturing, Catalent is committed to partnering with you to help bring molecules to market faster as optimal treatments for patients.
Advanced Oral Drug Delivery Technologies
With a wide range of advanced oral drug delivery technologies capable of overcoming of a variety of challenges including dose loading, taste masking, drug release and food effects, Catalent aims to deliver effective treatments and achieve optimal outcomes for innovators, prescribers, and patients. Catalent has the expertise to address your bioavailability, stability and manufacturability challenges across multiple technologies including softgels, Zydis® orally disintegrating tablets, FlexDoseSM stick packs as well as oral modified and controlled release delivery. We partner with you to select the right technology to realise the full potential of your treatment with a final dose form that best addresses the needs of all stakeholders and patients.
Oral Dose Analytical Solutions
Catalent offers a broad array of small and large molecule analytical solutions with specialised capabilities in handling challenging molecules, including controlled substances, highly potent compounds, and temperature, light, pH or oxygen-sensitive APIs. With extensive laboratory and stability chamber capacity, industry-recognised experts, and a suite of services ranging from compendial testing to extractables and leachables testing, Catalent provides tailored analytical solutions for stand-alone projects, and can help its partners advance their molecules from development to commercialisation.
Pulmonary and Nasal Delivery Solutions
Catalent Inhalation has the capabilities, expertise and state-of-the-art facilities to expedite product development, from concept and feasibility studies through commercial manufacture and release testing. With over 30 years of inhalation product experience, Catalent can handle the most complex projects and help bring your therapy to market, faster. Whether a single service or a comprehensive development package is required, Catalent offers end-to-end expertise in Dry Powder Inhalers (DPIs), unit-dose, bi-dose and multi-dose nasal sprays.
Catalent solves today’s clinical trial supply challenges and develops innovative solutions for the future. Catalent’s commitment to quality and service excellence is evident in its comprehensive and flexible solutions for small molecules, biologics and advanced therapy medicinal products (ATMPs). With modern global facilities, and 25+ years’ experience reliably supplying thousands of studies of all sizes and complexities around the world, services include:
- Clinical supply management
- Integrated formulation development, clinical manufacturing & blinding
- Specialty handling (potent, cytotoxic, controlled)
- Direct commercial product sourcing
- Clinical packaging/labelling
- Extensive clinical storage, cold chain capabilities & global distribution
- Demand-led supply
- Direct-to-patient solutions
- Clinical returns, reconciliation & destruction
For more information, visit www.catalent.com.
